Authorized purpose: CT and MRI image analysis, segmentation, visualization, and volumetry for adult abdominal treatment planning and follow-up, including liver surgery, living-donor, transplant, and oncologic workflows; it is not a diagnostic viewer or PACS replacement.
Clinical role
Interactive segmentation, visualization, volumetry, and surgical-strategy support.
Images and patients
CT/CTA · Liver
Key limitation
Keep in mind: The application is not a replacement for diagnostic review or PACS. AI-assisted semi-automatic tools have narrower labeled conditions, including restrictions described for healthy living-donor CT.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: CT and MRI image analysis, segmentation, visualization, and volumetry for adult abdominal treatment planning and follow-up, including liver surgery, living-donor, transplant, and oncologic workflows; it is not a diagnostic viewer or PACS replacement.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Liver Input: DICOM CT and MR abdominal image series meeting the labeled protocol requirements.
Who uses it?Intended users: Radiologists and surgeons.
What does the software produce?Output: Two-dimensional and three-dimensional visualizations, organ and lesion segmentations, volumetry, vascular territories, margins, and separation proposals.
What is its most important limitation?Key limitation: The application is not a replacement for diagnostic review or PACS. AI-assisted semi-automatic tools have narrower labeled conditions, including restrictions described for healthy living-donor CT.
Clinical takeaway. Clinical role: CT and MRI image analysis, segmentation, visualization, and volumetry for adult abdominal treatment planning and follow-up, including liver surgery, living-donor, transplant, and oncologic workflows; it is not a diagnostic viewer or PACS replacement.
Evidence takeaway. Evidence from the reviewed source record: Validation and verification covered successful testing of the performance and functionality of the subject device with respect to conformance to specifications. Human factors and usability engineering included formative and summative evaluation with the intended user group, and user acceptance tests were conducted. The AI pre-segmentation and volume calculation were validated, and the results of performance, functional, and validation testing demonstrate that the subject device meets the specification and intended use and is substantially equivalent. No clinical testing has been conducted to demonstrate substantial equivalence.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
CT and MRI image analysis, segmentation, visualization, and volumetry for adult abdominal treatment planning and follow-up, including liver surgery, living-donor, transplant, and oncologic workflows; it is not a diagnostic viewer or PACS replacement.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Two-dimensional and three-dimensional visualizations, organ and lesion segmentations, volumetry, vascular territories, margins, and separation proposals.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
The application is not a replacement for diagnostic review or PACS. AI-assisted semi-automatic tools have narrower labeled conditions, including restrictions described for healthy living-donor CT.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Validation and verification covered successful testing of the performance and functionality of the subject device with respect to conformance to specifications. Human factors and usability engineering included formative and summative evaluation with the intended user group, and user acceptance tests were conducted. The AI pre-segmentation and volume calculation were validated, and the results of performance, functional, and validation testing demonstrate that the subject device meets the specification and intended use and is substantially equivalent. No clinical testing has been conducted to demonstrate substantial equivalence.
Exact FDA submission
Checked 2026-09-19
The replacement uses only the exact packet's verification, validation, usability, acceptance, AI pre-segmentation, volume-calculation, substantial-equivalence, and clinical-testing statements.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Validation and verification covered successful testing of the performance and functionality of the subject device with respect to conformance to specifications. Human factors and usability engineering included formative and summative evaluation with the intended user group, and user acceptance tests were conducted. The AI pre-segmentation and volume calculation were validated, and the results of performance, functional, and validation testing demonstrate that the subject device meets the specification and intended use and is substantially equivalent. No clinical testing has been conducted to demonstrate substantial equivalence.
FDA source
Exact FDA submission
Checked 2026-09-19
The replacement uses only the exact packet's verification, validation, usability, acceptance, AI pre-segmentation, volume-calculation, substantial-equivalence, and clinical-testing statements.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232045. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM CT and MR abdominal image series meeting the labeled protocol requirements.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The cleared software imports DICOM CT and MR data and provides export options; MeVis describes the current family as vendor-neutral, but local interface compatibility requires qualification.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes MeVis Liver Suite as a standalone software application that can be installed on any PC running Windows 10 that meets the hardware requirements, used in an office environment in hospitals or medical practices. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "MeVis Liver Suite is a standalone software application that can be installed on any PC that runs on Windows 10 which meet the hardware requirements." … "The use environment is expected to be in an office environment under typical office conditions in hospitals or medical practices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Two-dimensional and three-dimensional visualizations, organ and lesion segmentations, volumetry, vascular territories, margins, and separation proposals.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Two-dimensional and three-dimensional visualizations, organ and lesion segmentations, volumetry, vascular territories, margins, and separation proposals.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes MeVis Liver Suite as a standalone software application that can be installed on any PC running Windows 10 that meets the hardware requirements, used in an office environment in hospitals or medical practices. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "MeVis Liver Suite is a standalone software application that can be installed on any PC that runs on Windows 10 which meet the hardware requirements." … "The use environment is expected to be in an office environment under typical office conditions in hospitals or medical practices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The cleared software imports DICOM CT and MR data and provides export options; MeVis describes the current family as vendor-neutral, but local interface compatibility requires qualification.
MeVis describes the current Liver Suite family as vendor-neutral CT and MRI DICOM analysis with interactive 2D/3D visualization, volumetry, surgical-strategy support, and export options.
product family · checked 2026-09-08
Confirm exact-release availability, interfaces, hosting, security, support, and commercial terms during procurement.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact packet identifies CT and MR scanning devices and does not establish the dossier's CT/CTA label. Controlled directory display reconciled from exact FDA wording: CT and MR. -> CT/CTA.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor product page, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K232045 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Provide quantitative and qualitative liver analysis and mean attenuation measurement to support clinician evaluation and assessment of fatty liver in patients aged 18-75 whose CT includes a significant part of the liver; not for diagnosis or risk assessment of fatty liver disease.
Authorized purpose: Hepatic VCAR analyzes CT liver images to assess liver morphology and liver lesions with automated liver, lobe, segment, lesion, and measurement tools that a clinician can edit and confirm.
Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Authorized purpose: uOmnispace.CT is software for viewing, manipulating, evaluating, and analyzing medical images within healthcare institutions. The FDA indication lists colon visualization, dental panoramic and paraxial reconstruction, lung and airway segmentation and quantitative parameters, nodule analysis, vessel and brain-perfusion analysis, heart and coronary analysis, calcium scoring, dynamic analysis, bone-structure labeling, liver evaluation, dual-energy processing, and cardiovascular combined analysis.
Modality
CT/CTA
Anatomy
Colon, jaw, lungs, airways, brain, heart, vessels, liver, spine, ribs, and other labeled CT regions
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.